Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetic interactions affect drug absorption, distribution, metabolism, and excretion, altering plasma levels and activity. For example, antacids reduce tetracycline efficacy by forming unabsorbable complexes. Pharmacodynamic interactions occur when drugs act at the same or related receptor sites, producing additive, synergistic, or antagonistic effects, such as two antihypertensive drugs creating greater hypotensive effects together.

Enzyme inhibition reduces drug metabolism, increasing plasma drug levels and toxicity risk. Ketoconazole inhibits CYP3A4, elevating levels of drugs metabolized by this enzyme, such as certain statins, increasing side effects like rhabdomyolysis. Similarly, ritonavir inhibits CYP3A4, requiring careful monitoring and dosage adjustments for affected medications.

Drug transporters regulate absorption and elimination of medications. Verapamil inhibits P-glycoprotein, a transporter protein, enhancing digoxin effects and potentially causing toxicity. Altered transporter activity can significantly impact drug bioavailability and clearance, necessitating dose modifications to maintain therapeutic efficacy and minimize adverse effects.

Yes, some drug interactions are therapeutically beneficial. Penicillin activity is enhanced when coadministered with probenecid, improving antibiotic efficacy. However, most interactions are undesirable, reducing drug effectiveness or increasing adverse effects. Healthcare professionals must distinguish beneficial from harmful interactions to optimize patient outcomes.

Enzyme induction increases metabolizing enzyme levels, reducing drug efficacy by accelerating metabolism. Rifampin induces CYP450 enzymes, decreasing oral contraceptive blood levels and effectiveness. Conversely, enzyme inhibition decreases metabolism, increasing drug levels and toxicity risk. Both mechanisms significantly impact therapeutic drug concentrations and require dosage adjustments.

The object drug is the medication whose activity is altered, while the agent drug or precipitant causes the alteration. Understanding this distinction helps clinicians predict interaction outcomes and adjust dosing accordingly. For instance, when ketoconazole (agent) inhibits metabolism of statins (object), statin levels rise, requiring dose reduction to prevent toxicity.

Therapeutic drug monitoring ensures safe and effective medication use by measuring plasma drug concentrations. When interactions alter drug metabolism or transport, monitoring helps clinicians detect unexpected concentration changes and adjust dosages proactively. This is especially critical for drugs with narrow therapeutic windows where small concentration changes significantly impact efficacy or toxicity.